Differences in the safety profiles of two low-molecular-weight heparins.
Ofosu
Frederick A
FA
Canadian Blood Services and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. ofosuf@mcmaster.ca
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D017762:Nadroparin / Q000008:administration & dosage / Q000009:adverse effects*; D019637:Orthopedic Procedures / Q000009:adverse effects*; D018570:Risk Assessment; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D017762:Nadroparin